MRx 102

Drug Profile

MRx 102

Alternative Names: MRx-102

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator MyeloRx
  • Class
  • Mechanism of Action DNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Cancer; Lymphoma; Malignant melanoma

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Lymphoma; Malignant melanoma

Most Recent Events

  • 11 Jul 2016 Preclinical trials in Malignant melanoma in USA (unspecified route)
  • 11 Jul 2016 Preclinical trials in Lymphoma in USA (unspecified route)
  • 11 Jul 2016 MRx 102 is still in preclinical trials for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top